Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Rheumatoid Arthritis

  Free Subscription


Articles published in Arthritis Res Ther

Retrieve available abstracts of 193 articles:
HTML format



Single Articles


    May 2022
  1. KNITZA J, Tascilar K, Vuillerme N, Eimer E, et al
    Accuracy and tolerability of self-sampling of capillary blood for analysis of inflammation and autoantibodies in rheumatoid arthritis patients-results from a randomized controlled trial.
    Arthritis Res Ther. 2022;24:125.
    PubMed     Abstract available


  2. SHI L, Wang J, Guo HX, Han XL, et al
    Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.
    Arthritis Res Ther. 2022;24:121.
    PubMed     Abstract available


  3. HERTRAMPF S, Klotsche J, Schefer Q, Glimm AM, et al
    Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFalpha therapy.
    Arthritis Res Ther. 2022;24:117.
    PubMed     Abstract available


  4. QIN Y, Wang Y, Meng F, Feng M, et al
    Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease.
    Arthritis Res Ther. 2022;24:115.
    PubMed     Abstract available


  5. KEINDL M, Davies R, Bergum B, Brun JG, et al
    Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjogren's syndrome.
    Arthritis Res Ther. 2022;24:101.
    PubMed     Abstract available


  6. SIGAUX J, Mathieu S, Nguyen Y, Sanchez P, et al
    Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis.
    Arthritis Res Ther. 2022;24:100.
    PubMed     Abstract available


    April 2022
  7. DE ARMAS-RILLO L, Quevedo-Abeledo JC, Hernandez-Hernandez V, de Vera-Gonzalez A, et al
    The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:99.
    PubMed     Abstract available


  8. KONDO F, Sugihara T, Umezawa N, Hasegawa H, et al
    Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still's disease.
    Arthritis Res Ther. 2022;24:92.
    PubMed     Abstract available


  9. SHARMA S, Plant D, Bowes J, Macgregor A, et al
    HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status.
    Arthritis Res Ther. 2022;24:90.
    PubMed     Abstract available


  10. BARTLETT SJ, Bingham CO, van Vollenhoven R, Murray C, et al
    The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Arthritis Res Ther. 2022;24:83.
    PubMed     Abstract available


    March 2022
  11. SAKURABA K, Omori Y, Kai K, Terada K, et al
    Risk factor analysis of perioperative complications in patients with rheumatoid arthritis undergoing primary cervical spine surgery.
    Arthritis Res Ther. 2022;24:79.
    PubMed     Abstract available


  12. JOO YB, Lee KB, Sul B, Lee HS, et al
    Effect of resistance exercise on serum leptin levels in a prospective longitudinal study of women patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:76.
    PubMed     Abstract available


  13. VAN DER LEEUW MS, Messelink MA, Tekstra J, Medina O, et al
    Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions.
    Arthritis Res Ther. 2022;24:74.
    PubMed     Abstract available


  14. HUSNI ME, Deodhar A, Schwartzman S, Chakravarty SD, et al
    Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Arthritis Res Ther. 2022;24:73.
    PubMed     Abstract available


  15. VITTECOQ O, Guillou C, Hardouin J, Gerard B, et al
    Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.
    Arthritis Res Ther. 2022;24:72.
    PubMed     Abstract available


  16. KENNEY HM, Wu CL, Loiselle AE, Xing L, et al
    Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.
    Arthritis Res Ther. 2022;24:64.
    PubMed     Abstract available


  17. OCHI S, Sonomoto K, Nakayamada S, Tanaka Y, et al
    Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Arthritis Res Ther. 2022;24:61.
    PubMed     Abstract available


    February 2022
  18. MILLIER MJ, Fanning NC, Frampton C, Stamp LK, et al
    Plasma interleukin-23 and circulating IL-17A(+)IFNgamma(+) ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:57.
    PubMed     Abstract available


  19. GOUZE H, Aegerter P, Said-Nahal R, Zins M, et al
    Rheumatoid arthritis, as a clinical disease, but not rheumatoid arthritis-associated autoimmunity, is linked to cardiovascular events.
    Arthritis Res Ther. 2022;24:56.
    PubMed     Abstract available


  20. SIMONS G, Caplan J, DiSantostefano RL, Veldwijk J, et al
    Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations.
    Arthritis Res Ther. 2022;24:55.
    PubMed     Abstract available


  21. FUJIWARA T, Kondo M, Yamada H, Haraguchi A, et al
    Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: results from the multicenter observational cohort study, FRANK Registry.
    Arthritis Res Ther. 2022;24:53.
    PubMed     Abstract available


  22. AHMAD HA, Baker JF, Conaghan PG, Emery P, et al
    Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
    Arthritis Res Ther. 2022;24:47.
    PubMed     Abstract available


  23. SORENSEN AS, Andersen MN, Juul-Madsen K, Brokso AD, et al
    Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis.
    Arthritis Res Ther. 2022;24:43.
    PubMed     Abstract available


  24. FIECHTER RH, Bolt JW, van de Sande MGH, Aalbers CJ, et al
    Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool.
    Arthritis Res Ther. 2022;24:36.
    PubMed     Abstract available


    January 2022
  25. WU YY, Li XF, Wu S, Niu XN, et al
    Role of the S100 protein family in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:35.
    PubMed     Abstract available


  26. REBIC N, Munro S, Garg R, Hazlewood G, et al
    "The medications are the decision-makers..." Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory.
    Arthritis Res Ther. 2022;24:31.
    PubMed     Abstract available


  27. GARCIA-MONTOYA L, Nam JL, Duquenne L, Villota-Eraso C, et al
    Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.
    Arthritis Res Ther. 2022;24:26.
    PubMed     Abstract available


  28. DE FRANCA NR, Menard HA, Lora M, Zhou Z, et al
    Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:23.
    PubMed     Abstract available


  29. BROUWERS H, von Hegedus JH, van der Linden E, Mahdad R, et al
    Hyaluronidase treatment of synovial fluid is required for accurate detection of inflammatory cells and soluble mediators.
    Arthritis Res Ther. 2022;24:18.
    PubMed     Abstract available


  30. VERSTAPPEN M, van Steenbergen HW, de Jong PHP, van der Helm-van Mil AHM, et al
    Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
    Arthritis Res Ther. 2022;24:4.
    PubMed     Abstract available


  31. MEEHAN M, Shah A, Lobo J, Oates J, et al
    Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:2.
    PubMed     Abstract available


  32. BINGHAM CO 3RD, Walker D, Nash P, Lee SJ, et al
    The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Arthritis Res Ther. 2022;24:11.
    PubMed     Abstract available


  33. SUGIYAMA T, Furuta S, Hiraguri M, Ikeda K, et al
    Latent class analysis of 216 patients with adult-onset Still's disease.
    Arthritis Res Ther. 2022;24:7.
    PubMed     Abstract available


    December 2021
  34. CUTOLO M, Soldano S, Gotelli E, Montagna P, et al
    CTLA4-Ig treatment induces M1-M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients.
    Arthritis Res Ther. 2021;23:306.
    PubMed     Abstract available


  35. ZHANG X, Feng R, Zhao J, Wang Y, et al
    Salivary gland ultrasonography in primary Sjogren's syndrome from diagnosis to clinical stratification: a multicentre study.
    Arthritis Res Ther. 2021;23:305.
    PubMed     Abstract available


  36. MOLINA COLLADA J, Lopez Gloria K, Castrejon I, Nieto-Gonzalez JC, et al
    Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development.
    Arthritis Res Ther. 2021;23:299.
    PubMed     Abstract available


  37. LI R, Liu X, Chen G, Tang G, et al
    Clinical phenotypes and prognostic factors of adult-onset Still's disease: data from a large inpatient cohort.
    Arthritis Res Ther. 2021;23:300.
    PubMed     Abstract available


    November 2021
  38. GEROSSIER E, Nayar S, Froidevaux S, Smith CG, et al
    Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:289.
    PubMed     Abstract available


  39. DOUMEN M, De Cock D, Pazmino S, Bertrand D, et al
    Correction to: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:285.
    PubMed    


  40. REISER C, Klotsche J, Hospach A, Berendes R, et al
    First-year follow-up of children with chronic nonbacterial osteomyelitis-an analysis of the German National Pediatric Rheumatologic Database from 2009 to 2018.
    Arthritis Res Ther. 2021;23:281.
    PubMed     Abstract available


  41. LEE SY, Ibrahim F, Tom BDM, Nikiphorou E, et al
    Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial.
    Arthritis Res Ther. 2021;23:278.
    PubMed     Abstract available


    October 2021
  42. KOPPEJAN H, Hameetman M, Beyrend G, van Unen V, et al
    Immunoprofiling of early, untreated rheumatoid arthritis using mass cytometry reveals an activated basophil subset inversely linked to ACPA status.
    Arthritis Res Ther. 2021;23:272.
    PubMed     Abstract available


  43. MATSUSHITA T, Otani K, Oto Y, Takahashi Y, et al
    Sustained microglial activation in the area postrema of collagen-induced arthritis mice.
    Arthritis Res Ther. 2021;23:273.
    PubMed     Abstract available


  44. MICHAEL D, Diederik C, Sofia P, Delphine B, et al
    Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:269.
    PubMed     Abstract available


  45. LECHTENBOEHMER CA, Burkard T, Reichenbach S, Walker UA, et al
    Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:267.
    PubMed     Abstract available


  46. YIN G, Yang C, Wu G, Yu X, et al
    The protein-protein interaction between connective tissue growth factor and annexin A2 is relevant to pannus formation in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:266.
    PubMed     Abstract available


  47. TSEN SD, Springer LE, Sharmah Gautam K, Tang R, et al
    Non-invasive monitoring of arthritis treatment response via targeting of tyrosine-phosphorylated annexin A2 in chondrocytes.
    Arthritis Res Ther. 2021;23:265.
    PubMed     Abstract available


  48. COSTELLO RE, Humphreys JH, Sergeant JC, Haris M, et al
    Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targ
    Arthritis Res Ther. 2021;23:263.
    PubMed    


  49. GAN Y, Sun Y, Jin J, Wang Y, et al
    bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients.
    Arthritis Res Ther. 2021;23:261.
    PubMed     Abstract available


  50. HAN S, Kim NR, Kang JW, Eun JS, et al
    Radial BMD and serum CTX-I can predict the progression of carotid plaque in rheumatoid arthritis: a 3-year prospective cohort study.
    Arthritis Res Ther. 2021;23:258.
    PubMed     Abstract available


  51. WANG Q, Che N, Lu C, Sun X, et al
    Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:257.
    PubMed     Abstract available


  52. WAHBI A, Tessoulin B, Bretonniere C, Boileau J, et al
    Catastrophic adult-onset Still's disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis.
    Arthritis Res Ther. 2021;23:256.
    PubMed     Abstract available


  53. LEE S, Kang S, Eun Y, Won HH, et al
    Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis.
    Arthritis Res Ther. 2021;23:254.
    PubMed     Abstract available


    September 2021
  54. XU X, Geng L, Chen C, Kong W, et al
    Olfactory impairment in patients with primary Sjogren's syndrome and its correlation with organ involvement and immunological abnormalities.
    Arthritis Res Ther. 2021;23:250.
    PubMed     Abstract available


  55. FLEISCHMANN RM, Alvarez DF, Bock AE, Cronenberger C, et al
    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira(R)) or continuing biosimilar therapy: week 52-92 data from a randomized,
    Arthritis Res Ther. 2021;23:248.
    PubMed     Abstract available


  56. KIM GH, Park YJ
    Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:247.
    PubMed     Abstract available


  57. PETERSON MN, Dykhoff HJ, Crowson CS, Davis JM 3rd, et al
    Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study.
    Arthritis Res Ther. 2021;23:244.
    PubMed     Abstract available


  58. RIGBY W, Buckner JH, Louis Bridges S Jr, Nys M, et al
    HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
    Arthritis Res Ther. 2021;23:245.
    PubMed     Abstract available


  59. HAN Y, Wang J, Li S, Li Y, et al
    Isopsoralen ameliorates rheumatoid arthritis by targeting MIF.
    Arthritis Res Ther. 2021;23:243.
    PubMed     Abstract available


  60. MARKLEIN B, Jenning M, Konthur Z, Haupl T, et al
    The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.
    Arthritis Res Ther. 2021;23:239.
    PubMed     Abstract available


  61. MEASE PJ, Stryker S, Liu M, Salim B, et al
    Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
    Arthritis Res Ther. 2021;23:236.
    PubMed     Abstract available


  62. REIJM S, Kissel T, Stoeken-Rijsbergen G, Slot LM, et al
    Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load.
    Arthritis Res Ther. 2021;23:230.
    PubMed     Abstract available


    August 2021
  63. HIROSE W, Harigai M, Amano K, Hidaka T, et al
    Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:228.
    PubMed     Abstract available


  64. TANAKA Y, Takeuchi T, Izutsu H, Kaneko Y, et al
    Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:221.
    PubMed     Abstract available


  65. WANG Y, Chen S, Zheng S, Lin J, et al
    The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical applica
    Arthritis Res Ther. 2021;23:212.
    PubMed     Abstract available


  66. COSTELLO RE, Humphreys JH, Sergeant JC, Haris M, et al
    Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PRE
    Arthritis Res Ther. 2021;23:210.
    PubMed     Abstract available


  67. WESTERLIND H, Palmqvist I, Saevarsdottir S, Alfredsson L, et al
    Is tea consumption associated with reduction of risk of rheumatoid arthritis? A Swedish case-control study.
    Arthritis Res Ther. 2021;23:209.
    PubMed     Abstract available


  68. TRANG DAMT, Okamura K, Suto T, Sakane H, et al
    Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
    Arthritis Res Ther. 2021;23:206.
    PubMed     Abstract available


    July 2021
  69. AJEGANOVA S, Andersson MLE, Frostegard J, Hafstrom I, et al
    Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
    Arthritis Res Ther. 2021;23:201.
    PubMed     Abstract available


  70. IWAMOTO N, Sato S, Kurushima S, Michitsuji T, et al
    Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:197.
    PubMed     Abstract available


  71. MINAMINO H, Katsushima M, Fujita Y, Hashimoto M, et al
    Comment on "Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study": authors' reply.
    Arthritis Res Ther. 2021;23:195.
    PubMed    


  72. STOCKFELT M, Lundell AC, Hetland ML, Ostergaard M, et al
    Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
    Arthritis Res Ther. 2021;23:189.
    PubMed     Abstract available


  73. ANDONIAN BJ, Johannemann A, Hubal MJ, Pober DM, et al
    Altered skeletal muscle metabolic pathways, age, systemic inflammation, and low cardiorespiratory fitness associate with improvements in disease activity following high-intensity interval training in persons with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:187.
    PubMed     Abstract available


  74. MESSELINK MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, et al
    Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon.
    Arthritis Res Ther. 2021;23:184.
    PubMed     Abstract available


  75. JUNG SY, Koh JH, Kim KJ, Park YW, et al
    Switching from TNFalpha inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFalpha inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
    Arthritis Res Ther. 2021;23:182.
    PubMed     Abstract available


  76. CORRADO A, Rotondo C, Mele A, Cici D, et al
    Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:180.
    PubMed     Abstract available


  77. KOO BS, Eun S, Shin K, Yoon H, et al
    Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.
    Arthritis Res Ther. 2021;23:178.
    PubMed     Abstract available


  78. PARK JK, Shon S, Yoo HJ, Suh DH, et al
    Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
    Arthritis Res Ther. 2021;23:177.
    PubMed     Abstract available


  79. CHO SK, Kim H, Lee J, Nam E, et al
    Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.
    Arthritis Res Ther. 2021;23:176.
    PubMed     Abstract available


    June 2021
  80. MAARSEVEEN TD, Maurits MP, Niemantsverdriet E, van der Helm-van Mil AHM, et al
    Handwork vs machine: a comparison of rheumatoid arthritis patient populations as identified from EHR free-text by diagnosis extraction through machine-learning or traditional criteria-based chart review.
    Arthritis Res Ther. 2021;23:174.
    PubMed     Abstract available


  81. EBERHARD A, Bergman S, Mandl T, Olofsson T, et al
    Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study.
    Arthritis Res Ther. 2021;23:169.
    PubMed     Abstract available


  82. HUR B, Gupta VK, Huang H, Wright KA, et al
    Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.
    Arthritis Res Ther. 2021;23:164.
    PubMed     Abstract available


  83. DEMORUELLE MK, Wang H, Davis RL, Visser A, et al
    Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:163.
    PubMed     Abstract available


  84. FERRAZ-AMARO I, Corrales A, Quevedo-Abeledo JC, Vegas-Revenga N, et al
    Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk.
    Arthritis Res Ther. 2021;23:162.
    PubMed     Abstract available


  85. GIOLLO A, Cioffi G, Ognibeni F, Orsolini G, et al
    Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:158.
    PubMed     Abstract available


  86. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
    Serum TNFalpha levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
    Arthritis Res Ther. 2021;23:154.
    PubMed     Abstract available


    May 2021
  87. RICHTER JG, Chehab G, Schwartz C, Ricken E, et al
    The PICASO cloud platform for improved holistic care in rheumatoid arthritis treatment-experiences of patients and clinicians.
    Arthritis Res Ther. 2021;23:151.
    PubMed     Abstract available


  88. MATSUMOTO H, Fujita Y, Matsuoka N, Temmoku J, et al
    Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD).
    Arthritis Res Ther. 2021;23:148.
    PubMed     Abstract available


  89. OLIVER J, Nair N, Orozco G, Smith S, et al
    Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Arthritis Res Ther. 2021;23:139.
    PubMed    


    April 2021
  90. JIN S, Li M, Wang Q, Zeng X, et al
    Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT.
    Arthritis Res Ther. 2021;23:127.
    PubMed     Abstract available


  91. SEGU-VERGES C, Coma M, Kessel C, Smeets S, et al
    Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
    Arthritis Res Ther. 2021;23:126.
    PubMed     Abstract available


  92. KIM KW, Kim BM, Won JY, Min HK, et al
    Regulation of osteoclastogenesis by mast cell in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:124.
    PubMed     Abstract available


  93. COMBE B, Allanore Y, Alten R, Caporali R, et al
    Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
    Arthritis Res Ther. 2021;23:119.
    PubMed     Abstract available


  94. JINNO S, Onishi A, Dubreuil M, Hashimoto M, et al
    Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2021;23:116.
    PubMed     Abstract available


  95. ZHU J, Niu Z, Alfredsson L, Klareskog L, et al
    Age at menarche, age at natural menopause, and risk of rheumatoid arthritis - a Mendelian randomization study.
    Arthritis Res Ther. 2021;23:108.
    PubMed     Abstract available


  96. MATSUMOTO Y, Shivappa N, Sugioka Y, Tada M, et al
    Change in dietary inflammatory index score is associated with control of long-term rheumatoid arthritis disease activity in a Japanese cohort: the TOMORROW study.
    Arthritis Res Ther. 2021;23:105.
    PubMed     Abstract available


  97. AKGUL A, Maddaloni M, Jun SM, Nelson AS, et al
    Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:99.
    PubMed     Abstract available


    March 2021
  98. WAN L, Gao Y, Gu J, Chi H, et al
    Total metabolic lesion volume of lymph nodes measured by (18)F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still's disease.
    Arthritis Res Ther. 2021;23:97.
    PubMed     Abstract available


  99. MINAMINO H, Katsushima M, Hashimoto M, Fujita Y, et al
    Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study.
    Arthritis Res Ther. 2021;23:96.
    PubMed     Abstract available


  100. RISTIC GG, Subota V, Stanisavljevic D, Vojvodic D, et al
    Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:95.
    PubMed     Abstract available


  101. WEISEL K, Berger S, Thorn K, Taylor PC, et al
    A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:85.
    PubMed     Abstract available


  102. OIIVER J, Nair N, Orozco G, Smith S, et al
    Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Arthritis Res Ther. 2021;23:80.
    PubMed     Abstract available


    February 2021
  103. TOYAMA S, Tokunaga D, Tsuchida S, Kushida R, et al
    Comprehensive assessment of alterations in hand deformities over 11 years in patients with rheumatoid arthritis using cluster analysis and analysis of covariance.
    Arthritis Res Ther. 2021;23:66.
    PubMed     Abstract available


  104. VODENCAREVIC A, Tascilar K, Hartmann F, Reiser M, et al
    Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
    Arthritis Res Ther. 2021;23:67.
    PubMed     Abstract available


  105. CONTRERAS-YANEZ I, Lavielle P, Clark P, Pascual-Ramos V, et al
    Markers of disease severity and positive family history are associated to significant risk perception in rheumatoid arthritis, while compliance with therapy is not: a cross-sectional study in 415 Mexican outpatients.
    Arthritis Res Ther. 2021;23:61.
    PubMed     Abstract available


  106. LIU M, Xie Z, Sun G, Chen L, et al
    Macrophage migration inhibitory factor may play a protective role in osteoarthritis.
    Arthritis Res Ther. 2021;23:59.
    PubMed     Abstract available


  107. NOWELL WB, Gavigan K, Kannowski CL, Cai Z, et al
    Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.
    Arthritis Res Ther. 2021;23:53.
    PubMed     Abstract available


  108. KAY J, Jaworski J, Wojciechowski R, Wiland P, et al
    Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
    Arthritis Res Ther. 2021;23:51.
    PubMed     Abstract available


  109. TERSLEV L, Brahe CH, Ostergaard M, Fana V, et al
    Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission.
    Arthritis Res Ther. 2021;23:48.
    PubMed     Abstract available


    January 2021
  110. TAN LK, Too CL, Diaz-Gallo LM, Wahinuddin S, et al
    The spectrum of association in HLA region with rheumatoid arthritis in a diverse Asian population: evidence from the MyEIRA case-control study.
    Arthritis Res Ther. 2021;23:46.
    PubMed     Abstract available


  111. HEMSHEKHAR M, Anaparti V, El-Gabalawy H, Mookherjee N, et al
    A bioavailable form of curcumin, in combination with vitamin-D- and omega-3-enriched diet, modifies disease onset and outcomes in a murine model of collagen-induced arthritis.
    Arthritis Res Ther. 2021;23:39.
    PubMed     Abstract available


  112. WU C, Tan S, Liu L, Cheng S, et al
    Transcriptome-wide association study identifies susceptibility genes for rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:38.
    PubMed     Abstract available


  113. FROSTEGARD J, Ahmed S, Hafstrom I, Ajeganova S, et al
    Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms.
    Arthritis Res Ther. 2021;23:32.
    PubMed     Abstract available


  114. MUN S, Lee J, Park M, Shin J, et al
    Serum biomarker panel for the diagnosis of rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:31.
    PubMed     Abstract available


  115. WRIGHT M, Smed MK, Nelson JL, Olsen J, et al
    Is gene expression among women with rheumatoid arthritis dysregulated during a postpartum flare?
    Arthritis Res Ther. 2021;23:30.
    PubMed     Abstract available


  116. RYDELL E, Forslind K, Nilsson JA, Karlsson M, et al
    Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study.
    Arthritis Res Ther. 2021;23:27.
    PubMed     Abstract available


  117. SOLOMON DH, Xu C, Collins J, Kim SC, et al
    The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy.
    Arthritis Res Ther. 2021;23:26.
    PubMed     Abstract available


  118. MURRAY K, Turk M, Alammari Y, Young F, et al
    Long-term remission and biologic persistence rates: 12-year real-world data.
    Arthritis Res Ther. 2021;23:25.
    PubMed     Abstract available


  119. SIMON TA, Dong L, Winthrop KL
    Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data.
    Arthritis Res Ther. 2021;23:17.
    PubMed     Abstract available


  120. DAVIGNON JL, Combe B, Cantagrel A
    Cytomegalovirus infection: friend or foe in rheumatoid arthritis?
    Arthritis Res Ther. 2021;23:16.
    PubMed     Abstract available


  121. DROBINSKI PJ, Bay-Jensen AC, Karsdal MA, Sardar S, et al
    Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
    Arthritis Res Ther. 2021;23:13.
    PubMed     Abstract available


  122. KAMEDA H, Takeuchi T, Yamaoka K, Oribe M, et al
    Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Arthritis Res Ther. 2021;23:9.
    PubMed     Abstract available


  123. EMERY P, Durez P, Hueber AJ, de la Torre I, et al
    Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
    Arthritis Res Ther. 2021;23:3.
    PubMed     Abstract available


  124. ROHRICH DC, van de Wetering EHM, Rennings AJ, Arts EE, et al
    Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study.
    Arthritis Res Ther. 2021;23:2.
    PubMed     Abstract available


  125. CURTIS JR, Weinblatt ME, Shadick NA, Brahe CH, et al
    Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
    Arthritis Res Ther. 2021;23:1.
    PubMed     Abstract available


    December 2020
  126. BYWALL KS, Kihlbom U, Hansson M, Falahee M, et al
    Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients.
    Arthritis Res Ther. 2020;22:288.
    PubMed     Abstract available


  127. CHOI C, Jeong W, Ghang B, Park Y, et al
    Correction to: Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:287.
    PubMed    


  128. NOVELLA-NAVARRO M, Plasencia C, Tornero C, Navarro-Compan V, et al
    Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:284.
    PubMed     Abstract available


  129. CURTIS JR, Xie F, Crowson CS, Sasso EH, et al
    Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.
    Arthritis Res Ther. 2020;22:282.
    PubMed     Abstract available


    November 2020
  130. NOSRATI Z, Bergamo M, Rodriguez-Rodriguez C, Saatchi K, et al
    Refinement and validation of infrared thermal imaging (IRT): a non-invasive technique to measure disease activity in a mouse model of rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:281.
    PubMed     Abstract available


  131. VERSTAPPEN M, Niemantsverdriet E, Matthijssen XME, le Cessie S, et al
    Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:276.
    PubMed     Abstract available


  132. CHOI C, Jeong W, Ghang B, Park Y, et al
    Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:275.
    PubMed     Abstract available


  133. DAKKAK YJ, Niemantsverdriet E, van der Helm-van Mil AHM, Reijnierse M, et al
    Increased frequency of intermetatarsal and submetatarsal bursitis in early rheumatoid arthritis: a large case-controlled MRI study.
    Arthritis Res Ther. 2020;22:277.
    PubMed     Abstract available


  134. ROOS LJUNGBERG K, Borjesson E, Martinsson K, Wettero J, et al
    Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:274.
    PubMed     Abstract available


  135. MURATA K, Ito H, Hashimoto M, Murakami K, et al
    Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort.
    Arthritis Res Ther. 2020;22:268.
    PubMed     Abstract available


    October 2020
  136. SAUER BC, Chen W, Xu Y, Shen J, et al
    Empirical evidence of disease activity thresholds used to indicate need for major therapeutic change in US veterans with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:253.
    PubMed     Abstract available


  137. HOU SM, Chen PC, Lin CM, Fang ML, et al
    CXCL1 contributes to IL-6 expression in osteoarthritis and rheumatoid arthritis synovial fibroblasts by CXCR2, c-Raf, MAPK, and AP-1 pathway.
    Arthritis Res Ther. 2020;22:251.
    PubMed     Abstract available


  138. TAKEUCHI T, Tanaka Y, Erdman J, Kaneko Y, et al
    ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
    Arthritis Res Ther. 2020;22:252.
    PubMed     Abstract available


  139. STRAND V, Boklage SH, Kimura T, Joly F, et al
    High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Arthritis Res Ther. 2020;22:250.
    PubMed     Abstract available


  140. ALDRIDGE J, Ekwall AH, Mark L, Bergstrom B, et al
    T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3(+)Th2 phenotype.
    Arthritis Res Ther. 2020;22:245.
    PubMed     Abstract available


  141. CURTIS JR, Xie F, Zhou H, Salchert D, et al
    Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available.
    Arthritis Res Ther. 2020;22:242.
    PubMed     Abstract available


  142. STRAND V, Kaine J, Alten R, Wallenstein G, et al
    Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Arthritis Res Ther. 2020;22:243.
    PubMed     Abstract available


  143. THUDIUM CS, Bay-Jensen AC, Cahya S, Dow ER, et al
    The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:235.
    PubMed     Abstract available


  144. PFEIL A, Nussbaum A, Renz DM, Hoffmann T, et al
    Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.
    Arthritis Res Ther. 2020;22:229.
    PubMed     Abstract available


  145. WANG Y, Zhang K, Yuan X, Xu N, et al
    miR-431-5p regulates cell proliferation and apoptosis in fibroblast-like synoviocytes in rheumatoid arthritis by targeting XIAP.
    Arthritis Res Ther. 2020;22:231.
    PubMed     Abstract available


    September 2020
  146. GENITSARIDI I, Flouri I, Plexousakis D, Marias K, et al
    Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
    Arthritis Res Ther. 2020;22:226.
    PubMed     Abstract available


  147. SALAFFI F, Di Carlo M, Carotti M, Ceccarelli L, et al
    Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication.
    Arthritis Res Ther. 2020;22:227.
    PubMed     Abstract available


  148. TOUSSIROT E, Marotte H, Mulleman D, Cormier G, et al
    Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study.
    Arthritis Res Ther. 2020;22:224.
    PubMed     Abstract available


  149. MIN HK, Won JY, Kim BM, Lee KA, et al
    Interleukin (IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK/IkappaBalpha pathway.
    Arthritis Res Ther. 2020;22:222.
    PubMed     Abstract available


  150. XUE J, Xu L, Zhu H, Bai M, et al
    CD14(+)CD16(-) monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK.
    Arthritis Res Ther. 2020;22:221.
    PubMed     Abstract available


  151. VAN BOHEEMEN L, Bolt JW, Ter Wee MM, de Jong HM, et al
    Patients' and rheumatologists' perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis.
    Arthritis Res Ther. 2020;22:217.
    PubMed     Abstract available


    August 2020
  152. XU J, Jiang C, Cai Y, Guo Y, et al
    Intervening upregulated SLC7A5 could mitigate inflammatory mediator by mTOR-P70S6K signal in rheumatoid arthritis synoviocytes.
    Arthritis Res Ther. 2020;22:200.
    PubMed     Abstract available


  153. JULIA A, Avila G, Celis R, Sanmarti R, et al
    Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:196.
    PubMed     Abstract available


  154. SMOLEN JS, Kang YM, Yoo WH, Emery P, et al
    Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:188.
    PubMed     Abstract available


  155. YANG X, Guo Q, Feng T, Lu Q, et al
    IL13Ralpha1 protects against rheumatoid arthritis by combating the apoptotic resistance of fibroblast-like synoviocytes.
    Arthritis Res Ther. 2020;22:184.
    PubMed     Abstract available


    July 2020
  156. TACHIBANA M, Yonemoto Y, Okamura K, Suto T, et al
    Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
    Arthritis Res Ther. 2020;22:178.
    PubMed     Abstract available


  157. PARK JK, Jang YJ, Oh BR, Shin J, et al
    Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:176.
    PubMed     Abstract available


  158. REED E, Hedstrom AK, Hansson M, Mathsson-Alm L, et al
    Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
    Arthritis Res Ther. 2020;22:170.
    PubMed     Abstract available


  159. EMERY P, Tanaka Y, Cardillo T, Schlichting D, et al
    Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:166.
    PubMed     Abstract available


    June 2020
  160. OTA T, Ota SI, Uchino A, Nagano S, et al
    IgG anti-hinge antibodies against IgG4 F(ab')2 fragments generated using pepsin are useful diagnostic markers for rheumatoid arthritis: implications of the possible roles of metalloproteinases and IgG subclasses in generating immunogenic hinge epitope
    Arthritis Res Ther. 2020;22:161.
    PubMed     Abstract available


  161. MA MHY, Defranoux N, Li W, Sasso EH, et al
    A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:158.
    PubMed     Abstract available


  162. TAKEUCHI T, Tanaka Y, Tanaka S, Kawakami A, et al
    Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
    Arthritis Res Ther. 2020;22:155.
    PubMed     Abstract available


  163. JIANG X, Alfredsson L
    Modifiable environmental exposure and risk of rheumatoid arthritis-current evidence from genetic studies.
    Arthritis Res Ther. 2020;22:154.
    PubMed     Abstract available


  164. HA YJ, Lee SM, Mun CH, Kim HJ, et al
    Methotrexate-loaded multifunctional nanoparticles with near-infrared irradiation for the treatment of rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:146.
    PubMed     Abstract available


  165. EBINA K, Hirano T, Maeda Y, Yamamoto W, et al
    Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
    Arthritis Res Ther. 2020;22:142.
    PubMed     Abstract available


  166. GENOVESE MC, Fleischmann R, Kivitz A, Lee EB, et al
    Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Arthritis Res Ther. 2020;22:139.
    PubMed     Abstract available


  167. STRAND V, Pope J, Tundia N, Friedman A, et al
    Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Arthritis Res Ther. 2020;22:137.
    PubMed     Abstract available


  168. KAWABE A, Nakano K, Kubo S, Asakawa T, et al
    Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
    Arthritis Res Ther. 2020;22:136.
    PubMed     Abstract available


    May 2020
  169. EMERY P, Tanaka Y, Cardillo T, Schlichting D, et al
    Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:115.
    PubMed     Abstract available


  170. LEE HR, Yoo SJ, Kim J, Yoo IS, et al
    The effect of nicotinamide adenine dinucleotide phosphate oxidase 4 on migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:116.
    PubMed     Abstract available


  171. SONG YJ, Choi IA, Meylan F, Demoruelle MK, et al
    Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF.
    Arthritis Res Ther. 2020;22:106.
    PubMed     Abstract available


  172. JARLBORG M, Courvoisier DS, Lamacchia C, Martinez Prat L, et al
    Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.
    Arthritis Res Ther. 2020;22:105.
    PubMed     Abstract available


  173. ZHANG H, Zhang H, Gao D, Xie W, et al
    Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.
    Arthritis Res Ther. 2020;22:100.
    PubMed     Abstract available


    April 2020
  174. VINSON D, Molet-Benhamou L, Degboe Y, den Broeder A, et al
    Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis.
    Arthritis Res Ther. 2020;22:97.
    PubMed     Abstract available


  175. DIERCKX S, Sokolova T, Lauwerys BR, Avramovska A, et al
    Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
    Arthritis Res Ther. 2020;22:96.
    PubMed     Abstract available


  176. TUNCEL J, Holmberg J, Haag S, Hopkins MH, et al
    Self-reactive T cells induce and perpetuate chronic relapsing arthritis.
    Arthritis Res Ther. 2020;22:95.
    PubMed     Abstract available


  177. WIBETOE G, Sexton J, Ikdahl E, Rollefstad S, et al
    Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models.
    Arthritis Res Ther. 2020;22:90.
    PubMed     Abstract available


  178. YATES M, Bechman K, Dennison EM, MacGregor AJ, et al
    Data quality predicts care quality: findings from a national clinical audit.
    Arthritis Res Ther. 2020;22:87.
    PubMed     Abstract available


  179. FUJITA Y, Asano T, Matsuoka N, Temmoku J, et al
    Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients.
    Arthritis Res Ther. 2020;22:80.
    PubMed     Abstract available


  180. KIM EK, Min HK, Lee SY, Kim DS, et al
    Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome.
    Arthritis Res Ther. 2020;22:77.
    PubMed     Abstract available


  181. GABAY C, Burmester GR, Strand V, Msihid J, et al
    Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Arthritis Res Ther. 2020;22:70.
    PubMed     Abstract available


  182. DAKKAK YJ, Boer AC, Boeters DM, Niemantsverdriet E, et al
    The relation between physical joint examination and MRI-depicted inflammation of metatarsophalangeal joints in early arthritis.
    Arthritis Res Ther. 2020;22:67.
    PubMed     Abstract available


    March 2020
  183. LIU PC, Ssu CT, Tsao YP, Liou TL, et al
    Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
    Arthritis Res Ther. 2020;22:64.
    PubMed     Abstract available


  184. SUN W, Ma J, Zhao H, Xiao C, et al
    Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA-146a-5p in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:61.
    PubMed     Abstract available


  185. GENOVESE MC, Sanchez-Burson J, Oh M, Balazs E, et al
    Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:60.
    PubMed     Abstract available


  186. BOETERS DM, van der Helm-van Mil AHM
    Response to: "Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation" by Masi and Fleischmann.
    Arthritis Res Ther. 2020;22:55.
    PubMed    


    February 2020
  187. DURET PM, Meyer N, Saraux A, Devauchelle-Pensec V, et al
    Seasonal effect on fatigue, pain and dryness in primary Sjogren's syndrome.
    Arthritis Res Ther. 2020;22:39.
    PubMed     Abstract available


  188. LACOMBE V, Lacout C, Lozac'h P, Ghali A, et al
    Unstimulated whole saliva flow for diagnosis of primary Sjogren's syndrome: time to revisit the threshold?
    Arthritis Res Ther. 2020;22:38.
    PubMed     Abstract available


  189. TRIMOVA G, Yamagata K, Iwata S, Hirata S, et al
    Tumour necrosis factor alpha promotes secretion of 14-3-3eta by inducing necroptosis in macrophages.
    Arthritis Res Ther. 2020;22:24.
    PubMed     Abstract available


    January 2020
  190. TEN BRINCK RM, Boeters DM, van Steenbergen HW, van der Helm-van Mil AHM, et al
    Improvement of symptoms in clinically suspect arthralgia and resolution of subclinical joint inflammation: a longitudinal study in patients that did not progress to clinical arthritis.
    Arthritis Res Ther. 2020;22:11.
    PubMed     Abstract available


    January 2019
  191. FRENKEN M, Schleich C, Brinks R, Abrar DB, et al
    The value of the simplified RAMRIS-5 in early RA patients under methotrexate therapy using high-field MRI.
    Arthritis Res Ther. 2019;21:21.
    PubMed     Abstract available


  192. SZEKANECZ Z, Raterman HG, Petho Z, Lems WF, et al
    Common mechanisms and holistic care in atherosclerosis and osteoporosis.
    Arthritis Res Ther. 2019;21:15.
    PubMed     Abstract available


  193. HU Q, Shi H, Zeng T, Liu H, et al
    Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease.
    Arthritis Res Ther. 2019;21:9.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: